eFFECTOR Therapeutics, Inc.

EFTRDelisted Jul 19, 2024

Industry: Pharmaceutical Preparations
SEC CIK: 0001828522

SEC filings (opens in a new tab)

eFFECTOR Therapeutics, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $251.1K in total; no superinvestor held it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 18; Q2 2024, +1 vs. previous quarter
13F value: $251.1K; Reported value at the end of Q2 2024
Superinvestors holding: 0; At the end of Q2 2024

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2023: $0; −100.0% year over year
Net income, FY2023: -$35.8M; No comparable prior period
Free cash flow, FY2023: -$29.6M; No comparable prior period
Revenue, Q1 FY2024: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 5.72K; Shares sold short
Change: 0; 0.0% vs. previous
Days to cover: 32.34; At average daily volume

Superinvestors holding EFTR, Q2 2024

Go to the superinvestors tab

No superinvestor reported holding EFTR at the end of Q2 2024.

Latest insider trades

See all insider trades

Open-market purchases and sales by eFFECTOR Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 29, 2023 (view filing)5:07 PM ET	Nov 27	2 days	George Simeon and 5 others10% Owner	SSale	−609.2K	$0.6065	−$369.5K	−25.1%1.82M after	2 lots
Oct 6, 2022 (view filing)	Oct 4	2 days	Ehrlich Christopher BDirector	PPurchase	+346	$0.57	+$197.22	+1.0%35.2K after
Sep 27, 2022 (view filing)	Sep 26	1 day	Ehrlich Christopher BDirector	PPurchase	+18.9K	$0.55	+$10.4K	+117.9%34.9K after
Aug 3, 2022 (view filing)5:58 PM ET	Aug 1-3	2 days	Root Jonathan D and 4 others10% Owner	SSale	−114.3K	$0.7981	−$91.2K	−47.3%127.6K after	6 lots
Jul 29, 2022 (view filing)8:54 PM ET	Jul 28	1 day	Root Jonathan D and 4 others10% Owner	SSale	−32.5K	$0.892	−$29.0K	−19.9%131.0K after	2 lots
Jul 27, 2022 (view filing)6:20 PM ET	Jul 25-27	2 days	Root Jonathan D and 4 others10% Owner	SSale	−48.7K	$0.8945	−$43.6K	−27.0%132.0K after	6 lots
Jul 22, 2022 (view filing)6:03 PM ET	Jul 20-22	2 days	Root Jonathan D and 4 others10% Owner	SSale	−20.3K	$0.9609	−$19.5K	−13.2%133.5K after	6 lots
Jul 19, 2022 (view filing)4:54 PM ET	Jul 15-19	4 days	Root Jonathan D and 4 others10% Owner	SSale	−69.6K	$1.10	−$76.3K	−34.2%134.1K after	6 lots
Jun 27, 2022 (view filing)	Jun 23	4 days	Gallagher Brian M. Jr.Director	PPurchase	+30.0K	$1.59	+$47.7K	New position30.0K after
Jun 9, 2022 (view filing)	Jun 7	2 days	Worland Stephen TPresident and Chief Executive	PPurchase	+20.0K	$1.37	+$27.4K	+10.3%215.0K after

Top 10 13F holders, Q2 2024

See all 18 holders

The largest institutional positions in eFFECTOR Therapeutics, Inc. at the end of Q2 2024; share changes are against Q1 2024.

Institutions holding EFTR in Q2 2024
Institution	Shares	Value	% of portfolio	Change in shares	Action
Sabby Management, LLC	352,084	$102.1K	1.36%	+352,084	New
Carlyle Group Inc.	192,884	$55.9K	0.01%	00.0%	Unchanged
Parallel Advisors, LLC	67,738	$19.7K	0.00%	00.0%	Unchanged
UBS Group AG	61,667	$17.9K	0.00%	+61,667	New
Blackstone Group Inc.	52,343	$15.2K	0.00%	00.0%	Unchanged
Geode Capital Management, LLC	25,583	$7.42K	0.00%	+2,974+13.2%	Added
Vanguard Group Inc	25,070	$7.27K	0.00%	−67,395−72.9%	Reduced
HRT Financial LP	21,528	$6.00K	0.00%	+21,528	New
Jane Street Group, LLC	18,669	$5.42K	0.00%	+18,669	New
Virtu Financial LLC	18,021	$5.00K	0.00%	+18,021	New